研究者業績

中島 裕史

Hiroshi Nakajima

基本情報

所属
千葉大学 大学院医学研究院アレルギー・臨床免疫学講座 教授
学位
医学博士(1999年3月 千葉大学)

J-GLOBAL ID
201801007724448421
researchmap会員ID
B000347685

論文

 304
  • Junya Suzuki, Shunsuke Furuta, Yosuke Kameoka, Osamu Suzuki, Fuyu Ito, Kazuko Uno, Fukuko Kishi, Yoshio Yamakawa, Kazuyuki Matsushita, Takashi Miki, Hiroshi Nakajima, Kazuo Suzuki
    Microvascular Research 156 104720-104720 2024年11月  査読有り
  • Hiroki Furuya, Yosuke Toda, Arifumi Iwata, Mizuki Kanai, Kodai Kato, Takashi Kumagai, Takahiro Kageyama, Shigeru Tanaka, Lisa Fujimura, Akemi Sakamoto, Masahiko Hatano, Akira Suto, Kotaro Suzuki, Hiroshi Nakajima
    Nature communications 15(1) 5610-5610 2024年7月5日  
    Group 2 innate lymphoid cells (ILC2s) are a subset of innate lymphocytes that produce type 2 cytokines, including IL-4, IL-5, and IL-13. GATA3 is a critical transcription factor for ILC2 development at multiple stages. However, when and how GATA3 is induced to the levels required for ILC2 development remains unclear. Herein, we identify ILC2-specific GATA3-related tandem super-enhancers (G3SE) that induce high GATA3 in ILC2-committed precursors. G3SE-deficient mice exhibit ILC2 deficiency in the bone marrow, lung, liver, and small intestine with minimal impact on other ILC lineages or Th2 cells. Single-cell RNA-sequencing and subsequent flow cytometry analysis show that GATA3 induction mechanism, which is required for entering the ILC2 stage, is lost in IL-17RB+PD-1- late ILC2-committed precursor stage in G3SE-deficient mice. Cnot6l, part of the CCR4-NOT deadenylase complex, is a possible GATA3 target during ILC2 development. Our findings implicate a stage-specific regulatory mechanism for GATA3 expression during ILC2 development.
  • Takashi Kumagai, Arifumi Iwata, Hiroki Furuya, Kodai Kato, Atsushi Okabe, Yosuke Toda, Mizuki Kanai, Lisa Fujimura, Akemi Sakamoto, Takahiro Kageyama, Shigeru Tanaka, Akira Suto, Masahiko Hatano, Atsushi Kaneda, Hiroshi Nakajima
    Proceedings of the National Academy of Sciences of the United States of America 121(27) e2320727121 2024年7月2日  
    Asthma is a widespread airway disorder where GATA3-dependent Type-2 helper T (Th2) cells and group 2 innate lymphoid cells (ILC2s) play vital roles. Asthma-associated single nucleotide polymorphisms (SNPs) are enriched in a region located 926-970 kb downstream from GATA3 in the 10p14 (hG900). However, it is unknown how hG900 affects the pathogenesis of allergic airway inflammation. To investigate the roles of the asthma-associated GATA3 enhancer region in experimental allergic airway inflammation, we first examined the correlation between GATA3 expression and the activation of the hG900 region was analyzed by flow cytometry and ChIP-qPCR. We found that The activation of enhancers in the hG900 region was strongly correlated to the levels of GATA3 in human peripheral T cell subsets. We next generated mice lacking the mG900 region (mG900KO mice) were generated by the CRISPR-Cas9 system, and the development and function of helper T cells and ILCs in mG900KO mice were analyzed in steady-state conditions and allergic airway inflammation induced by papain or house dust mite (HDM). The deletion of the mG900 did not affect the development of lymphocytes in steady-state conditions or allergic airway inflammation induced by papain. However, mG900KO mice exhibited reduced allergic inflammation and Th2 differentiation in the HDM-induced allergic airway inflammation. The analysis of the chromatin conformation around Gata3 by circular chromosome conformation capture coupled to high-throughput sequencing (4C-seq) revealed that the mG900 region interacted with the transcription start site of Gata3 with an influencing chromatin conformation in Th2 cells. These findings indicate that the mG900 region plays a pivotal role in Th2 differentiation and thus enhances allergic airway inflammation.
  • Kazuya Abe, Taro Iwamoto, Kei Ikeda, Takahiro Sugiyama, Shunsuke Furuta, Go Saito, Hanae Wakabayashi, Hiroshi Nakajima
    Modern rheumatology case reports 2024年5月16日  
    Immune checkpoint inhibitors (ICIs) sometimes induce immune-related adverse events (irAEs), and arthritis is one of the irAE symptoms. Recently, crystal-induced arthritis, such as calcium pyrophosphate (CPP) crystal deposition disease and gout, has been reported to occur after ICI administration. However, the distinction between ICI-associated crystal arthritis and ICI-induced non-crystal arthritis is difficult because their symptoms are similar. Besides, optimal treatment for ICI-associated crystal arthritis has not been established. Here, we report a patient who developed CPP crystal arthritis twice after pembrolizumab (ICI) administration and was successfully treated with intra-articular glucocorticoid injection. He suffered arthritis and acute interstitial nephritis simultaneously after ICI administration. Musculoskeletal ultrasound of his affected joint suggests that his arthritis was crystal-induced arthritis, and arthrocentesis detected CPP crystal in synovial fluid. Thus, we diagnosed his arthritis as ICI-associated cystal arthritis. Therefore, our case encourages the use of musculoskeletal ultrasound in patients with arthritis after treatment with ICI because it may distinguish between ICI-associated crystal arthritis and ICI-induced non-crystal arthritis. Besides, ICI-associated crystal arthritis could be treatable by intra-articular glucocorticoid injection.
  • Yoshihiro Oya, Yasuyo Tanaka, Takuya Nakazawa, Ryutaro Matsumura, Deborah D Glass, Hiroshi Nakajima, Ethan M Shevach
    Journal of immunology (Baltimore, Md. : 1950) 2024年4月29日  
    Foxp3+ T regulatory (Treg) cells prevent allograft rejection and graft-versus-host disease. Although polyclonal Tregs have been used both in animal models and in humans, the fine specificity of their suppressive function is poorly defined. We have generated mouse recipient-derived alloantigen-specific Tregs in vitro and explored the fine specificity of their suppressive function and their mechanism of action in vitro and in vivo. In vitro, when alloantigen and peptide Ag were both presented on the same dendritic cell, both responses were suppressed by iTregs specific either for the alloantigen or for the peptide Ag. In vivo, iTreg suppression was limited to the cognate Ag, and no bystander suppression was observed when both allo-antigen and peptide Ag were present on the same dendritic cell. In vitro, alloantigen-specific Tregs captured cognate MHC but failed to capture noncognate MHC. Our results demonstrate that a polyclonal population of iTregs generated from naive T cells can mediate highly specific function in vivo and support the view that Treg therapy, even with unselected polyclonal populations, is likely to be target antigen-specific and that bystander responses to self-antigens or to infectious agents are unlikely.

MISC

 429

書籍等出版物

 9

講演・口頭発表等

 142

共同研究・競争的資金等の研究課題

 55

産業財産権

 3